POINT Biopharma Global Inc. Common Stock
PNT was delisted on the 26th of December, 2023.
34 hedge funds and large institutions have $248M invested in POINT Biopharma Global Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 3 closing their positions.
500% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 3
62% more funds holding
Funds holding: 21 → 34 (+13)
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
25% more capital invested
Capital invested by funds: $198M → $248M (+$49.9M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$70.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$17.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13.3M |
| 4 |
Franklin Resources
San Mateo,
California
|
+$9.12M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.53M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.47M |
| 3 |
PA
Perceptive Advisors
New York
|
-$2.35M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$159K |
PNT Hedge Fund Activity: Q3 2021 in Review
34 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in POINT Biopharma Global Inc. Common Stock (PNT) for Q3 2021, worth a combined $248M — up 25% from $198M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PNT positions and 3 closed out — a net gain of 15 holders — while 7 added to existing stakes and 5 trimmed.
The largest buyer was RA Capital Management, adding an estimated $70.8M. The largest seller was Wellington Management Group, exiting entirely with an estimated $3.53M sold.
- 34 institutional investors held POINT Biopharma Global Inc. Common Stock (PNT) as of Q3 2021, up from 21 in Q2 2021.
- Funds reported $248M of POINT Biopharma Global Inc. Common Stock stock for Q3 2021, up 25% quarter-over-quarter.
- 18 funds opened new POINT Biopharma Global Inc. Common Stock positions in Q3 2021 and 3 closed out, a net change of +15 holders.
- The largest POINT Biopharma Global Inc. Common Stock buyer in Q3 2021 was RA Capital Management, an estimated $70.8M added.
- The largest POINT Biopharma Global Inc. Common Stock seller in Q3 2021 was Wellington Management Group, an estimated $3.53M sold.
Based on aggregated 13F filings for Q3 2021.